Global Hemoglobinopathies Treatment Market 2019-2023 | Development of Gene Therapy to Boost Growth | Technavio
LONDON--(BUSINESS WIRE)--Jan 2, 2019--The global hemoglobinopathies treatment market is expected to post a CAGR of close to 11% during the period 2019-2023, according to the latest market research report by .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190102005501/en/
Technavio has published a new market research report on the global hemoglobinopathies treatment market from 2019-2023. (Graphic: Business Wire)
A key factor driving the growth of the global hemoglobinopathies treatment market is the rising awareness of SCD and thalassemia. These diseases are the major types of hemoglobinopathies, which are passed from parents to the offspring. The early detection of SCD and thalassemia aids in treating them more effectively. Therefore, government and non-government organizations are conducting awareness programs to avoid the delay in the diagnosis and the unawareness of the treatment options.
As per Technavio, the development of gene therapy will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other important trends and market drivers that will affect market growth over 2018-2022.
In this report, Technavio highlights the development of gene therapy as one of the key emerging trends in the global hemoglobinopathies treatment market:
Global hemoglobinopathies treatment market: Development of gene therapy
Regenerative medicines such as gene therapy are one of the most researched and advanced treatment methods. In gene therapy, the mutated gene is taken from the patient and is modified genetically in the laboratory, which is then administered back into the patient. Hence, the genetically modified gene replaces the mutated genes. Although only a few gene therapies are currently approved worldwide, they have proven to be highly effective for the treatment of various activities. Consequently, many companies are conducting clinical trials for the treatment of hemoglobinopathies. The advances of regenerative medicines in the clinical phases are expected to fuel the growth of the global hemoglobinopathies treatment market.
“Pharmaceutical companies are focusing on collaboration for the development of medications for the treatment of hemoglobinopathies. These strategic alliances can enhance R&D activities for new drugs for the management of hemoglobinopathies. Such initiatives are helping companies to develop advanced therapeutics, which can be introduced quickly into the market,” says a senior analyst at Technavio.
Global hemoglobinopathies treatment market: Segmentation analysis
This market research report segments the global hemoglobinopathies treatment market by type (sickle cell disease, and thalassemia), and geographical regions (APAC, EMEA, and the Americas).
The Americas region led the market in 2018 with a market share of over 40%, followed by EMEA and APAC respectively. Although the APAC region held the smallest share of the market in 2018, it is expected to register the highest incremental growth during the forecast period.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005501/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH GENETICS PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 01/02/2019 12:28 PM/DISC: 01/02/2019 12:28 PM